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Abstract. Background: STEMI with onset ≤12 hours, necessary to take Primary 
Percutaneous Coronary Intervention (pPCI), but if there is no facility, another therapy is 
fibrinolytic, to improve blood flow in the coronary artery and myocardial function, thus 
reducing infarction expansion. This is a retrospective study in STEMI patient’s onset ≤12 
hours, had performed successful fibrinolytic with Streptokinase (SK) and Alteplase (tPA) 
from January 2015 to August 2017. TIMI flow was assessed by coronary angiography. There 
were 54 patients who had performed successful fibrinolytic therapy with SK and tPA; each 
group had 27 patients. In the SK group, there were nine patients (33.3%) with TIMI flow 2 
and 18 patients (66.7%) with TIMI flow 3. While in the tPA group there were 11 patients 
(40.7%) with TIMI flow 2, 16 patients (59.3%) with TIMI flow 3, (p=0.573). There is no 
difference in TIMI flow between SK and tPA on STEMI patients after success fibrinolytic 
therapy. 
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Abstrak. STEMI dengan onset≤12 jam, diperlukan untuk mengambil Intervensi Koroner 
Perkutan Primer (pPCI), tetapi jika tidak ada fasilitas, terapi lain adalah fibrinolitik, untuk 
meningkatkan aliran darah di arteri koroner dan fungsi miokardial, sehingga mengurangi 
ekspansi infark. Ini adalah penelitian retrospektif pada pasien STEMI onset≤12 jam, telah 
berhasil fibrinolytic dengan Streptokinase (SK) dan Alteplase (tPA) dari Januari 2015 
hingga Agustus 2017. Aliran TIMI dinilai oleh angiografi koroner. Ada 54 pasien yang telah 
melakukan terapi fibrinolitik yang sukses dengan SK dan tPA; setiap kelompok memiliki 27 
pasien. Dalam kelompok SK, ada sembilan pasien (33,3%) dengan aliran TIMI 2 dan 18 
pasien (66,7%) dengan aliran TIMI 3. Sementara pada kelompok tPA ada 11 pasien (40,7%) 
dengan aliran TIMI 2, 16 pasien (59,3%) dengan aliran TIMI 3, (p = 0,573). Tidak ada 
perbedaan dalam aliran TIMI antara SK dan tPA pada pasien STEMI setelah terapi 
fibrinolitik sukses.    
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1. Introduction 
Fibrinolytic therapy is used to improve blood flow in the coronary due to occlusion caused by 
thrombus, thereby reducing infarction expansion, improving myocardial function in the patient 
with STEMI [1]. De Lemoss et al. (2001), compared the angiographic reperfusion assessment 
with the ST segment resolution assessment on the administration of SK with tPA. Both 
fibrinolytic agents have more ST-segment resolution correlations and a higher average IRA 
patency with TIMI flow 3. However, tPA has a better TIMI flow compared to SK [2]. The aim of 
this study was to assess and compare TIMI flow between fibrinolytic agents SK and tPA after 
successful fibrinolytic. 
2. Methodology 
We examined data from medical records of patients who treated at Haji Adam Malik General 
Hospital from January 2015 to July 2017. Samples were patients who had been diagnosed with 
STEMI onset ≤ 12 hours, which had successfully performed fibrinolytic therapy with SK or tPA, 
and given the same dual antiplatelet (Aspilet 160 mg and Clopidogrel 300 mg) before performed 
fibrinolytic therapy, then followed by five days of Enoxaparin. We examined early ECG recording 
and 90 minutes after fibrinolytic, laboratory examination, coronary angiography record. 
Succeed fibrinolytic is a decreased ST segment ≥ 50%, at least two paired leads, compare early 
ECG and 90-minute ECG after fibrinolytic. Then the whole sample is divided into two groups, 
first group with SK, and the second group with tPA. Assessment of TIMI flow was performed by 
two interventions cardiologist through a coronary angiography recording. 
The data are presented descriptively with frequency distribution and percentage for categorical 
data. While numerical data is presented with mean and Standard Deviation (SD) values for 
normally distributed data, while abnormally distributed data with the median. The normality test 
of numerical variables in all subjects will use Kolmogorov Smirnov (n> 50). Both categorical 
variables will be tested the correlation, whether there is a significant correlation. Analysis of 
statistical data using SPSS software version 20, p-value <0.05 is statistically significant. 
3. Results 
Total samples were 54 patients, and each group had 27 samples. The mean age was 53 years for 
the SK group and 56 years in the tPA group. Males were the largest sample, 48 patients (88.9%), 
which 25 patients (92.6%) in the SK group and 23 patients (85.2%) in the tPA group. Total risk 
factor for CHD was highest in age and smoking was 43 patients. 
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This study divided STEMI into two groups, anterior and Inferior STEMI. In the SK group, inferior 
STEMI compared to the anterior STEMI, 15 patients (55.6%) and 12 patients (44.4%). In the tPA 
group, Anterior STEMI was more that 19 patients (70.4%), compared with Inferior STEMI 8 
patients (29.6%). The onset of chest pain divided into four groups. The onset of chest pain was 
greater in the > 3-6 hour’s group, 25 patients (46.3%), of which 11 patients (40.7%) in the SK 
group and 14 patients (51.9%) in the tPA group. The second onset of chest pain group was 0-3 
hours, 21 patients (38.9%), 12 patients in the SK group (44.4%) while in the tPA group of 9 
patients (33.3%) (Table 1).  
In the laboratory characteristics were found statistically significant differences between the SK 
and tPA groups, there are MPV and cardiac enzymes (Troponin and CKMB). On the MPV 
assessment in the SK group, an average value was 9.56 fL, whereas in the tPA group was 9.99 fL 
(p value= 0.044). In the cardiac enzyme group with p-value = 0.000, which Troponin values were 
divided into two groups (+) and (-). 24 patients (44.4%) with positive troponin, which five patients 
(5%) in the SK group and 19 patients (70.4%) in the tPA group. The CKMB cardiac enzyme 
examination in this study was also significant with p-value = 0.003, whereas the median of the 
SK group was 35 units / L, while in the tPA group was 62 units / L (Table 1). 
 Twenty patients (37%) with TIMI flow 2, while 34 patients (63%) with TIMI flow 3. In the SK 
group, TIMI flow two there were nine patients (33.3%), and TIMI flow 3 is 18 patients (66.7%), 
while in the tPA group, 11 patients (40.7%) with TIMI flow 2 and 16 patients (59.3%) with TIMI 
flow 3. The TIMI flow ratio between SK and tPA was not was statistically significant with p-
value= 0,573 (table 2). The TIMI flow assessment was observed with two interventionists. The 
value of Kappa (κ) inter-observer variability is 0.623 (p-value = 0.000).  
Table 1 Baseline Characteristics 
Characteristics 
Fibrinolytic 
P Value SK 
(n=27) 
tPA 
(n=27) 
Age (mean±SD), 
years 
53±8 56±8 0,197* 
Male 25 (92,6) 23 (85,2) 0.334b 
CHD Risk Factors  
(n, %) 
Age 
Type 2 DM 
Hypertension 
Smoking 
Family History 
Dislipidemia 
 
 
20 (74,1) 
9 (33,3) 
9 (33,3) 
23 (85,2) 
1 (3,7) 
11 (40,7) 
 
 
23 (85,2) 
11 (40,7) 
12 (44,4) 
20 (74,1) 
- 
13 (48,1) 
 
 
0,311a 
0,573a 
0,420a 
0,311a 
0,500b 
0,584a 
STEMI (n, %) 
Anterior 
Inferior 
 
12 (44,4) 
15 (55,6) 
 
19 (70,4) 
8 (29,6) 
0,054a 
Onset of paint (h) 
4 (0,5-8) 
4 (1-
11,5) 
0,536# 
Onset of chest 
pain (n, %) 
 
 
 
 
 
0,460c 
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0 - 3 h 
> 3 - 6 h 
> 6 – 9 h 
> 9 – 12 h 
12 (44,4) 
11 (40,7) 
4 (14,8) 
- 
9 (33,3) 
14 (51,9) 
2 (7,4) 
2 (7,4) 
Killip (n, %) 
I 
II 
 
25 (92,6) 
2 (7,4) 
 
22 (81,5) 
5 (18,5) 
 
0.210b 
Hemoglobin, g/dL 14,70±1,
71 
14,73±1,
46 
0,952* 
Hematocrit, % 42,33±4,
42 
42,71±5,
19 
0,772* 
Leukocyte, /μL 12.3k±3.
2k 
12.3k±3.
2k 
0,980* 
Platelet, /μL 255k±46
k 
265k±54
k 
0,514* 
MPV, fL 
9,56±0,8
7 
9,99±0,6
7 
0.044* 
PDW, % 10.95±1,
65 
11,23±1,
43 
0,512* 
Troponin (n, %) 
(+) 
(-) 
 
5 (18,5) 
22 (81,5) 
 
19 (70,4) 
8 (29,6) 
0,000* 
CKMB, unit/L 
35 
(11-211) 
62 
(21-327) 
0.003# 
n: total samples; SK: Streptokinase; tPA: Alteplase; *Student t-Test;bFisher’s exact test; #Mann-Whitney; 
aPearson Chi-Square; bFisher’s exact test; cKruskal-Wallis Test 
 
Table 2 Comparison of TIMI Flow between Streptokinase and Alteplase 
TIMI 
flow 
(n, %) 
Fibrinolytic 
Total 
(n=54) 
p-value SK 
(n=27) 
tPA 
(n=27) 
2 
3 
9 (33,3) 
18 (66,7) 
11 (40,7) 
16 (59,3) 
20 (37) 
34 (63) 
0,573 
 
4. Discussion 
From the baseline characteristics found that men were most often found in STEMI, with a total 
of 48 people (88.9%). Previous research says that the number of STEMI events is more common 
in man as much as 3-4 times compared with the woman [3], [4]. The average age was 54 years 
old, with the lowest age range 46 years old, and the highest age of 62 years old. An increasing in 
age risk factor, the incidence of cardiovascular disease also increases [4].  
This study was divided into two major groups, anterior and inferior STEMI. Where overall 
anterior STEMI was greater than inferior. The results of this study are consistent with those of 
Kennedy et al. (1979), anterior STEMI is more common when compared with inferior STEMI 
[5]. The results showed that STEMI patients came with an average of 3 to 6 hours of onset, with 
a total of 25 patients (46.3%), of which 11 were fibrinolytic with SK and 14 with tPA, with median 
4 hours, the onset range of 0.5 hours to 11.5 hours. Then followed by an onset of fewer than 3 
hours, amounting to 21 patients (38.9%), with 12 patients performed fibrinolytic with SK and 
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nine other patients with TPA. Compared with previous studies, where the high-fibrinolytic 
efficacy of onset<6 hours, and fibrinolytic action with onset <3 hours, the results given almost 
the same as the pPCI [4]. 
The results of laboratory tests are significant, i.e. MPV, Troponin and CKMB. The average value 
of MPV from 2 large groups of fibrinolytic equal to 9.77 fL (p-value = 0.044). From this results 
it can be concluded that the initial value of MPV is low, the fibrinolytic success rate is higher. 
MPV describes platelet function, the study of Bath et al. (1996), assessed that high MPV was 
more aggressive in responding to platelet aggregation, resulting in lower MPV values, decreased 
platelet adhesion, resulting in increased fibrinolytic success [6], [7].  
Another assessment of laboratory tests that was statistically significant was troponin levels. In 
this study troponin assessment was only based on the presence or absence of Troponin, due to the 
examination of different type of troponin, Troponin T and Troponin I. From this study it was 
found that the levels of Troponin (-) were higher than the troponin (+), 30 patients (55, 6%) with 
24 patients (44.4%) with p = 0,000. The results are consistent with the onset of chest pain <6 
hours, with the median onset of chest pain that is 4 hours. Levels of troponin in STEMI patients 
increased in peripheral blood 3-4 hours of onset of infarction and persisted for up to 2 weeks [4]. 
The total 54 samples, 34 patients (63%) were obtained with TIMI flow 3, of which 18 were using 
SK and 16 with TPA. The results were slightly different from the previous research done by de 
Lemos et al. (2001), which compared the TIMI flow between the administration of TPA and SK 
in the TIMI-14 and HIT-4 studies. From these two studies mentioned that TIMI flow 2 and three 
more in the group TPA, whereas in this study TIMI flow three more on giving SK. The difference 
of this study with previous, possibly due to anticoagulant before coronary angiography action, 
thus affecting TIMI flow at the time of coronary angiography. The p-value obtained is 0.573, 
meaning that there is no difference of TIMI flow between giving of SK and TPA [2]. TIMI flow 
assessment is subjective, to assess the magnitude of the difference between the two observers the 
Kappa test was used to see the difference between the observed agreement. From this research 
got a value of Kappa (K) 0,623, it means a good inter-observer agreement [8]. 
5. Conclusion 
From this study, we can conclude that there is no difference of TIMI flow between SK and TPA 
on STEMI patients after successful fibrinolytic therapy. 
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